NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting, IMMUNOLOGY2026.
The new data presented highlight that LANCL2 medicines have the potential to prevent asthma exacerbations. In this article, we detail novel asthma-focused results presented at IMMUNOLOGY2026, along with additional findings highlighting the broader therapeutic potential of LANCL2 medicines across inflammatory and autoimmune diseases, including lupus, multiple sclerosis and psoriasis. The article also outlines our planned next steps, including an upcoming presentation of new clinical and translational findings outlining the therapeutic efficacy of LANCL2 medicines in IBD at the upcoming Digestive Disease Week® (DDW), where we will further share progress on this platform.
Read more about the findings and what lies ahead in the article below.
Read More
